As a result, CA IX has emerged as a relevant biomarker and therapeutic target for bladder cancer, with several CA IX‐specific inhibitors currently under investigation for their potential to improve treatment response in this malignancy. The gene discussed is CA9; the disease is urinary bladder carcinoma.